Moreover, prospective clinical trials are needed to validate the clinical utility of incorporating SDF-1α into routine practice, which could revolutionize the management approach to AML in the elderly, ultimately improving both therapeutic outcomes and quality of life for this vulnerable patient population. This evidence concerns the gene CXCL12 and acute myeloid leukemia.